US Stock MarketDetailed Quotes
SCYX Scynexis
- 1.200
- +0.010+0.84%
Close Nov 22 16:00 ET
- 1.200
- 0.0000.00%
Post 20:01 ET
45.54MMarket Cap-1621P/E (TTM)
1.230High1.170Low148.10KVolume1.180Open1.190Pre Close177.34KTurnover0.42%Turnover Ratio0.86P/E (Static)37.95MShares3.07052wk High0.78P/B42.39MFloat Cap1.15052wk Low--Dividend TTM35.32MShs Float150.000Historical High--Div YieldTTM5.04%Amplitude1.150Historical Low1.197Avg Price1Lot Size
About Scynexis Company
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Company Profile
SymbolSCYX
Company NameScynexis
Listing DateMay 2, 2014
Issue Price10.00
Founded1999
CEODr. David Angulo, M.D.
MarketNASDAQ
Employees29
Fiscal Year Ends12-31
Address1 Evertrust Plaza,13th floor
CityJersey City
ProvinceNew Jersey
CountryUnited States of America
Zip Code07302-6548
Phone1-201-884-5485
Websitehttp://www.scynexis.com
Company Executives
- Name
- Position
- Salary
- Dr. David Angulo, M.D.
- Chief Executive Officer, President and Director
- 1.21M
- Ivor Macleod, C.P.A.,M.B.A.
- Chief Financial Officer and Principal Accounting Officer
- 626.90K
- Guy Macdonald
- Chairman of the Board
- 128.75K
- Brian Philippe Tinmouth
- Independent Director
- 95.25K
- David C. Hastings
- Independent Director
- 104.25K
- Armando Anido
- Independent Director
- 98.75K
- Dr. Steven C. Gilman, PhD
- Independent Director
- 106.25K
- Dr. Ann F. Hanham,PhD
- Independent Director
- 105.25K
- Scott Sukenick
- General Counsel
- 936.70K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data